What it is
Crystagen is a thymus derivative — a bioregulator drawn from the thymus, a gland behind the breastbone that trains the immune system's T-cells. Its purpose is to normalise how the immune system works, to help cells repair damaged DNA, and to keep gene activity healthy, particularly in immune tissue.
The word "normalise" is doing real work there. Crystagen is not described as boosting immunity. It is described as correcting it in either direction: bringing an underactive immune system up and an overactive one down.
As for what a bioregulator is: these are peptides — amino acid chains — but much shorter than most peptides. Being smaller means there is less for the immune system to object to, so the risk of provoking an unwanted immune response is lower. And they act differently. Ordinary peptides signal to cells from outside, and the effect fades as the peptide clears. A bioregulator is matched to a specific tissue, binds to DNA inside that tissue's cells, and changes which genes are running. Because those genes control repair, regeneration, and ageing, the effects are presented as more foundational and longer-lasting than a peptide's, which works only while it is present.
It comes as a dry powder in a 20 milligram vial, mixed with bacteriostatic water — sterile water with a preservative so the mixed liquid keeps for weeks — and injected just under the skin.
Crystagen is a thymus-derived peptide bioregulator, described as normalising immune function, enhancing DNA repair processes, and maintaining healthy gene expression with particular reference to the immune system.
The distinguishing framing for Crystagen is bidirectional immunomodulation rather than immunostimulation — the stated action is normalisation of immune responses in both hypoactive and hyperactive states. That framing is what makes the interaction profile coherent, and it is also what makes it cautionary: a compound that modulates in both directions has unpredictable effects in someone whose immune system is already being deliberately pushed one way.
The class argument sits somewhat awkwardly on this particular compound. Bioregulators are said to be safer than longer peptides precisely because their brevity gives the immune system little to recognise — an argument about avoiding immune attention, applied here to a compound whose whole purpose is to change immune behaviour. Setting that aside, the mechanism claimed is intracellular and genetic rather than extracellular and signalling: the compound is described as reaching DNA inside thymus-derived and immune tissue and altering which genes those cells express, so that the effect persists past clearance instead of ending with it, since the genes concerned are those of repair, regeneration, and longevity. Which genes, and on what evidence, has not been established.
Presentation: 20 mg lyophilised vial reconstituted with bacteriostatic water, subcutaneous, dosed at bedtime on a 20-day course repeated 3–4 times per year.
What it does
The central action is on the immune system, in both directions. It helps normalise immune responses whether they are too weak or too strong. It supports the maturation and activity of T-cells — the white blood cells that recognise specific threats and coordinate the response — and activates the B-cell response, the arm of immunity that produces antibodies. It also improves immune surveillance, the constant patrol that spots infected or abnormal cells.
From that follow the practical effects: better resistance to infections, to immune imbalances of the autoimmune kind, and to the decline in immunity that comes with age; fewer inflammatory and infectious complications; and faster recovery after illness, surgery, or a period of stress.
The second strand is DNA. It stimulates the enzymes that repair DNA, reduces the damage done by oxidative stress, toxins, and ageing, and prevents mutations in cells — all of which promotes genomic stability, meaning the DNA stays intact and accurate as cells divide.
The third strand is ageing. It protects immune cells from senescence — the age-related deterioration where a cell stops working properly — and from dying before their time, and it is described as geroprotective, meaning protective against ageing itself.
It is also named as a supportive therapy in cancer-related conditions and in recovery after chemotherapy or radiation, and as helpful in long-running infections, autoimmune conditions, or degenerative disease. Note that the supportive-therapy claim sits directly against one of its own contraindications, which is discussed in the avoidance section below.
Finally, it increases resistance to environmental, physical, and psychological stress, and is positioned both preventatively and supportively for ageing people whose immune function is declining, and as a general anti-ageing measure.
Bidirectional immune normalisation is the organising claim: correction of both hypoactive and hyperactive immune states. Supporting actions named are T-cell maturation and activity, activation of the B-cell immune response, and improved immune surveillance.
Clinical immune outcomes: improved resistance to infection, to autoimmune imbalance, and to age-related immune decline; reduction of inflammatory and infectious complications; improved recovery following illness, surgery, or stress; stated utility in chronic infection, autoimmune conditions, and degenerative disease.
Genomic: stimulation of DNA repair enzymes; reduced damage from oxidative stress, toxins, and ageing; prevention of cellular mutation with promotion of genomic stability.
Senescence and geroprotection: protection of immune cells from senescence and premature cell death; stated geroprotective benefit; contribution to healthy ageing and resilience; positioning as both preventative and supportive in ageing populations with declining immune function, and as a general anti-ageing intervention.
Oncological: described as an ideal supportive therapy in oncological conditions and as having a role in post-chemotherapy or post-radiation recovery. Read that against its own contraindication, which states that stimulating immune or cell proliferation during an active malignancy is potentially risky and requires physician clearance and monitoring. The two positions have not been reconciled; the contraindication is the more specific and the more cautious.
Stress: increased resistance to environmental, physical, and psychological stressors.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Helps normalise immune responses whether the immune system is underactive or overactive.Anecdotal
- Increases resistance to stress and general resilience.Anecdotal
- Improves recovery following illness, surgery, or a period of stress.Anecdotal
- Supports the maturation and activity of T-cells, the white blood cells that recognise specific threats.Animal or lab only
- Reduces inflammatory and infectious complications.Anecdotal
- Offers geroprotective benefits — protection against the effects of ageing.Anecdotal
- Activates the B-cell immune response, the arm of the immune system that makes antibodies.Anecdotal
- Improves resistance to infections, to autoimmune imbalances, and to the decline in immunity that comes with age.Anecdotal
- Stimulates the enzymes that repair DNA.Anecdotal
- Reduces the damage done by oxidative stress, toxins, and ageing.Anecdotal
- Prevents mutations in cells and promotes genomic stability — DNA staying intact and accurate as cells divide.Anecdotal
- Protects immune cells from age-related deterioration and from dying prematurely.Anecdotal
- Contributes to healthy ageing and overall resilience.Anecdotal
- Described as an ideal supportive therapy in cancer-related conditions. Read this alongside the warning about active cancer, in the avoidance section.Anecdotal
- Improves immune surveillance — the constant patrol for infected or abnormal cells.Anecdotal
- Helpful in the treatment of long-running infections, autoimmune conditions, or degenerative diseases.Anecdotal
- Plays a role in recovery after chemotherapy or radiation.Anecdotal
- Increases the body's resistance to environmental, physical, and psychological stress, and is used both preventatively and supportively in ageing people with declining immune function, and as a general anti-ageing measure.Anecdotal
- Normalises immune responses in both hypoactive and hyperactive states.Anecdotal
- Increases stress resistance and resilience.Anecdotal
- Improves recovery following illness, surgery, or stress.Anecdotal
- Supports T-cell maturation and activity.Animal or lab only
- Reduces inflammatory and infectious complications.Anecdotal
- Geroprotective benefit.Anecdotal
- Activates the B-cell immune response.Anecdotal
- Improves resistance to infection, autoimmune imbalance, and age-related immune decline.Anecdotal
- Stimulates DNA repair enzymes.Anecdotal
- Reduces damage from oxidative stress, toxins, and ageing.Anecdotal
- Prevents cellular mutation; promotes genomic stability.Anecdotal
- Protects immune cells from senescence and premature cell death.Anecdotal
- Contributes to healthy ageing and resilience.Anecdotal
- Described as an ideal supportive therapy in oncological conditions — in tension with its own active-malignancy contraindication, discussed below.Anecdotal
- Improves immune surveillance.Anecdotal
- Utility in chronic infection, autoimmune conditions, and degenerative disease.Anecdotal
- Role in post-chemotherapy and post-radiation recovery.Anecdotal
- Increases resistance to environmental, physical, and psychological stressors; preventative and supportive in ageing populations with declining immune function, and as a general anti-ageing intervention.Anecdotal
Reconstitution and dosing
The vial holds 20 milligrams (mg). Mix it with 2 millilitres (mL) of bacteriostatic water. On an insulin syringe that is the 200 mark, because 100 units is 1 mL. Add the water slowly down the inside wall of the vial rather than onto the powder, then swirl gently. Do not shake.
With 20 mg in 2 mL, every unit on the syringe holds 100 micrograms. So 1 milligram is 10 units.
Inject under the skin, once a day, at bedtime, two hours after your last meal.
There is one protocol and one dose: 1 milligram a day for 20 days. Nothing ramps up or down.
The cycle runs 20 days and the recommendation is to repeat it three or four times a year.
Notice how little of the vial a course uses. Twenty days at 1 milligram is 20 milligrams — exactly one vial for a whole course, and only a fifth of the vial's worth of solution used each week.
No reason has been given for the bedtime timing or the two-hour gap after eating, and there is no guidance on what to do if you miss a day.
Presentation: 20 mg vial reconstituted with 2 mL (200 units) of bacteriostatic water, giving 10 mg/mL — 100 mcg per insulin unit. Add diluent down the vial wall and swirl; do not shake.
Recomputed draw: 1 mg = 10 units. Exact; the single dose level carries no discrepancy.
Administration: subcutaneous, once daily at bedtime, two hours after the last meal. No rationale is given for either constraint.
Protocol: flat 1 mg daily for 20 days, no titration. Cycle repeated 3–4 times per year.
Exposure: 20 mg per course — exactly one vial, with the reconstituted solution in use across the full 20 days. That is a longer in-use period for a reconstituted vial than most protocols on this site require, and no storage or stability guidance for the solution is available beyond the reconstitution step. Bacteriostatic water is preserved for multi-dose use, which is the implicit basis, but this has not been addressed directly.
Note the dose is half that of the other 20 mg bioregulators on this site running comparable courses, most of which sit at 2 mg daily. No reason for the difference has been given.
No missed-dose guidance is given.
20 mg vial
Mix with 2 mL (200 units) of BAC water, giving 10 mg/mL — 100 mcg per insulin unit. One vial covers a full 20-day course.
10 mg/mL · 100 mcg per unit
Cycle: 20-day cycle; repeat 3–4 times per year · Frequency: 1×/day at bedtime, 2 hours after the last meal; subcutaneous
| When | Dose | Draw | How often |
|---|---|---|---|
| Days 1–20 (1 mg) | 1 mg | 10 units | 1×/day |
20 mg in 2 mL is 10 mg/mL, or 100 mcg per unit. Draw 10 units (0.1 mL) for 1000 mcg.
Who should avoid it
- Anyone pregnant or breastfeeding.
- Anyone sensitive to peptides or peptide by-products. Hypersensitivity is treated as an indication of a probable allergic response to the peptide or its components.
- Anyone with late-stage kidney or liver failure.
- Anyone with an active cancer needs a doctor's clearance first, and close monitoring throughout. The reasoning is worth reading in full: although Crystagen has shown some anti-tumour properties, stimulating the immune system or cell growth while a cancer is active is potentially risky. Note this sits against the benefits list, which calls it an ideal supportive therapy in cancer-related conditions. The two views have not been reconciled; the contraindication is the more careful one.
- Take great care if you have an autoimmune condition such as lupus, rheumatoid arthritis, or multiple sclerosis. Because Crystagen changes how the immune system behaves, it could in theory make those conditions worse, and extreme caution is advised along with and close monitoring.
- Take care if you are on **immunosuppressants** — medicines that deliberately damp down the immune system — or if you have had an organ transplant. The result may be unpredictable. This is the most serious of the interaction warnings: Crystagen's stated purpose is to normalise immune function, and an immunosuppressant's purpose is to keep it suppressed, so the two work against each other.
- Take care if you have an acute infection or **sepsis** — the body's overwhelming, dangerous response to an infection. Crystagen may cause an unpredictable reaction from the body in that situation.
- Talk to a doctor before starting, and go through your full medication list with them.
- Pregnancy and lactation: contraindicated.
- Hypersensitivity to any peptide or peptide by-product, treated as indicating a probable allergic response to the compound or its components.
- Late-stage renal or hepatic failure.
- Active malignancy: requires physician clearance and close monitoring throughout. The reasoning is that stimulating immune or cell proliferation during active disease is potentially risky notwithstanding the stated anti-tumour properties. This directly qualifies the benefits list's oncological supportive-therapy claim; the contraindication is the more specific statement.
- Autoimmune conditions — lupus, rheumatoid arthritis, multiple sclerosis are named: theoretical exacerbation through immune modulation, requiring extreme caution and close monitoring.
- Immunosuppressant therapy or organ transplantation: caution, with unforeseen results stated as the risk. Mechanistically this is the most consequential item here — a compound whose stated purpose is bidirectional immune normalisation is directly at odds with deliberate pharmacological immunosuppression.
- Acute infection or sepsis: unpredictable host response.
- No monitoring parameters are specified for any of the above, and no discontinuation criteria are given.
Side effects
- A reaction where you inject — redness, swelling, or itching.
- An allergic reaction. This is rare; stop using it if one occurs.
- The list is short for a compound that changes immune function, and no monitoring is suggested. Given the warnings above about autoimmune conditions, any flare of an existing immune condition would be worth acting on.
- No guidance is available on what to watch for during the course, or on when to stop other than for an allergic reaction.
- Injection site reaction: erythema, swelling, and/or pruritus.
- Allergic reaction — rare; discontinue on occurrence.
- The adverse effect list is notably thin relative to the breadth of the interaction and contraindication sections. For an immunomodulator, flare of underlying autoimmune disease is the foreseeable event and it appears only in the interaction list, not here.
- No monitoring parameters, and no discontinuation criteria beyond allergic reaction.
User reports
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
Not an established pairing — no stacks have been defined for Crystagen. Listed because Vilon is the other thymus-derived bioregulator on this site, and the two overlap heavily — both act on T-cells and immune balance. That overlap is a reason for care rather than enthusiasm: doubling up on immune modulation is exactly what this page's warnings are about.
Not an established pairing; listed as the nearest neighbour. Vilon is the site's other thymus-derived bioregulator, with overlapping T-cell and immune-regulation claims. The overlap argues for caution rather than combination — the autoimmune, immunosuppression, and acute infection cautions on this page apply with more force to concurrent immunomodulators, and the pairing has not been studied.
Named indirectly. The Pancragen page on this site says that combining it with immune-acting compounds may temporarily heighten immune sensitivity, and Crystagen is one such compound. So the caution comes from the Pancragen entry rather than from Crystagen's own interaction data.
Cross-referenced from the Pancragen page on this site, which states that combination with immune-acting agents may temporarily heighten immune sensitivity. Crystagen falls squarely in that category. The caution originates there, not here — Crystagen's own interaction list makes no mention of other bioregulators.
- No established stacks
No stacks have been established for Crystagen. Everything known about combining Crystagen with anything else is a warning, not a suggestion. The entries above are cross-references, not recommendations.
No stacking data exists for Crystagen; the only combination content is a uniformly cautionary interaction list covering autoimmune disease, immunosuppression, and acute infection. The entries above are editorial cross-references.
Dosing figures have been reviewed and units are recomputed from the stated protocol.